World Rare Disease Day: GEXVal Presents Posters at 5th Tsukuba Co-creation Conference

2026年3月3日 2026年7月22日

wpmaster

株式會社GEXVal
March 3, 2026

World Rare Disease Day: GEXVal Presents Two Posters at 5th Tsukuba Co-creation Conference

GEXVal Inc. (President & CEO: Juran Kato, PhD; Fujisawa, Kanagawa, Japan; hereinafter “GEXVal”) is pleased to announce that that, in observance of World Rare Disease Day, it participated in the 5th Tsukuba Co-creation Conference, held at the Astellas Pharma Tsukuba Research Center (Tsukuba, Ibaraki, Japan), and presented two posters at the poster session.

[Event Overview]
The Tsukuba Co-creation Conference is a collaborative forum jointly hosted by five pharmaceutical companies with research facilities in Tsukuba (Astellas Pharma, Eisai, Ono Pharmaceutical, Taiho Pharmaceutical, and Nippon Shinyaku) and the University of Tsukuba Co-creation Place. The 5th Conference was held under the theme "Rare Disease Conditions — Creating a Future Where No One Is Left Behind," bringing together patient advocates, clinical researchers, basic scientists, and pharmaceutical industry professionals to share perspectives on the challenges and unmet needs in rare condition diagnosis and treatment.

**Presentation Details**

Conference	The 5th Tsukuba Co-Creation Conference Rare Diseases: Building a Future Where No One Is Left Behind
Date	March 3, 2026
Venue	Astellas Pharma Inc., Tsukuba Research Center
Poster Presentation	Data-Driven Indication Discovery for Rare Diseases Using AI Agent Technology Yusuke Nakayama¹, Shingo Tsuji², Koji Yamamoto³, Juran Kato¹, and Kouichi Hosomi⁴ ¹GEXVal Inc.; ²RCAST, The University of Tokyo; ³Independent Researcher; ⁴Faculty of Pharmacy, Kindai University Preclinical and Clinical Evaluation of a Novel GPCR Modulator in Fragile X Syndrome Takako Naito¹, Yusuke Nakayama¹, Takashi Arima¹, Guido Hanauer¹, Ajay Duggal^{1, 2}, Kim Prescott^{1, 2}, Mike Tranfaglia^{3, 4}, Patricia Cogram⁴, and Juran Kato-Suzuki^{1, 5} ¹GEXVal Inc.; ²Adnovate Clinical; ³FRAXA Research Foundation; ⁴FRAXA Drug Validation Initiative and Institute of Ecology and Biodiversity, University of Santiago, Chile; ⁵GEXVal AU Pty Ltd

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com

分類: 信息

World Rare Disease Day: GEXVal Presents Posters at 5th Tsukuba Co-creation Conference

World Rare Disease Day: GEXVal Presents Two Posters at 5th Tsukuba Co-creation Conference

Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation

CTO Nakayama Contributes Invited Article to Experimental Medicine, Japan’s Leading Life Science Journal, on AI-Driven Drug Discovery